epothilone B (EPO906)

01/01/2001 - "In order to foster the design of improved derivatives, the potential biotransformation products of epothilone B formed in liver of tumor-bearing mice after intravenous administration of 10 mg/kg were characterized in an early stage of compound development. "
07/01/2009 - "Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study."
11/01/2008 - "In both rats and mice, a single i.v. bolus injection of patupilone (1.5-4 mg/kg) rapidly distributed from plasma to all tissues and was slowly eliminated from muscle, liver and small intestine, but showed longer retention in tumor and brain with no apparent elimination over 24 h. "
09/01/2003 - "The improved efficacy was matched by reduced tumor IFP and a 3-fold increase in the tumor levels of EPO906. "
06/01/2013 - "Patupilone was generally well tolerated in patients with advanced solid tumors with no newly occurring safety events compared to previous clinical studies. "

01/15/2002 - "The present study further explores the mechanisms underlying epothilone B-mediated cytotoxicity in human breast cancer cells. "
01/01/2011 - "Patupilone showed antitumor activity in triple-negative breast cancer."
01/15/2002 - "Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells."
04/01/2014 - "Phase II trial of patupilone in patients with brain metastases from breast cancer."
06/01/2010 - "The epothilone B analog ixabepilone acts to stabilize microtubules and demonstrates antitumor activity in recent breast cancer studies. "

03/01/2011 - "Here, we have assessed the efficacy of the microtubule inhibiting agent epothilone B on glioblastoma cell motility, a prerequisite cellular program of invasive glioblastomas. "
09/01/2008 - "In vitro methods with glioblastoma cells varying in p53 status were used to assess the efficacy of epothilone B to induce anti-neoplastic responses. "
08/15/2012 - "We have thus demonstrated that patupilone antagonizes glioblastoma cell migration by a novel mechanism, which is distinct from suppression of MT dynamic instability. "
08/15/2012 - "At non-cytotoxic concentrations, patupilone inhibited glioblastoma cell movement, as shown by transwell cell migration, random motility and spheroid assays. "
08/15/2012 - "Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends."

11/01/2005 - "These data suggest that patupilone holds promise for prostate cancer treatment."
11/15/2010 - "Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells."
03/01/2009 - "Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer."
11/01/2005 - "Patupilone was administered to athymic mice bearing human prostate cancer xenografts (subcutaneous DU 145 and PC-3M, orthotopic PC-3M). "
02/01/2009 - "In the setting of castrate metastatic prostate cancer, ixabepilone and patupilone showed encouraging clinical activity in the phase II setting and further studies are needed to determine if they provide additional clinical benefit to patients with advanced disease."

01/01/2005 - "In this study, we investigated the in vitro and in vivo efficacy of patupilone (epothilone B, EPO906), a novel nontaxane microtubule stabilizing agent, in treatment of multiple myeloma (MM). "
01/01/2005 - "Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo."